首页> 外国专利> human thrombopoietin derivative novel in vivo platelet growth efficacy has been improved

human thrombopoietin derivative novel in vivo platelet growth efficacy has been improved

机译:人血小板生成素衍生物在体内新的血小板生长功效得到改善

摘要

The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.
机译:本发明涉及新的人血小板生成素(hTPO)衍生物,及其制备方法。特别地,通过用氨基酸例如天冬酰胺替代天然hTPO中特定位置的氨基酸,将糖链引入天然hTPO中,制备具有高活性的新型hTPO衍生物,其增强了体内血小板的产生。因此,本发明的新的hTPO衍生物可用于治疗与抗癌疗法有关的血小板减少症或骨髓移植。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号